Showing 20 of 25 recruiting trials for “mixed-phenotype-acute-leukemia”
A Study of Revumenib and Mezigdomide in People With Leukemia
👨⚕️ Eytan Stein, MD, Memorial Sloan Kettering Cancer Center📍 10 sites📅 Started Jan 2026View details ↗
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
👨⚕️ Filippo Milano, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Sep 2025View details ↗
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingNCT06899581 ↗
Gut Health in Children With Cancer
🏥 Great Ormond Street Hospital for Children NHS Foundation Trust📍 1 site📅 Started Jan 2025View details ↗
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
👨⚕️ Erlie Jiang, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jan 2025View details ↗
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
👨⚕️ Annie P Im, University of Pittsburgh Cancer Institute LAO📍 4 sites📅 Started Dec 2024View details ↗
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
👨⚕️ Ann Dahlberg, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Jul 2024View details ↗
Venetoclax Combined With Azactidine in the Treatment of ALAL
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
👨⚕️ Margaret MacMillan, University of Minnesota Masonic Cancer Center📍 1 site📅 Started May 2023View details ↗
Allo HSCT Using RIC and PTCy for Hematological Diseases
👨⚕️ Mark Juckett, University of Minnesota Masonic Cancer Center📍 1 site📅 Started May 2023View details ↗
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
👨⚕️ Mary-Beth M. Percival, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Feb 2022View details ↗
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
👨⚕️ Marie Bleakley, Fred Hutch/University of Washington Cancer Consortium📍 10 sites📅 Started Aug 2019View details ↗
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
👨⚕️ Timothy Olson, MD, PhD, Children's Hospital of Philadelphia📍 1 site📅 Started Mar 2019View details ↗
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
👨⚕️ John Perentesis, MD, Children's Hospital Medical Center, Cincinnati📍 1 site📅 Started Dec 2018View details ↗
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →